Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.682 EUR 1.79% Market Closed
Market Cap: 28.3m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

EV/FCFF
Enterprise Value to FCFF

-2.1
Current
-0.6
Median
3.9
Industry
Lower than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-2.1
=
Enterprise Value
22.2m EUR
/
FCFF
-10.4m EUR
All Countries
Close
Market Cap EV/FCFF
BE
Celyad Oncology SA
XBRU:CYAD
28.3m EUR -2.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -241 279.4
US
Abbvie Inc
NYSE:ABBV
320.5B USD 23.8
US
Amgen Inc
NASDAQ:AMGN
140.8B USD 30
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD 10.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD -72.3
US
Epizyme Inc
F:EPE
94.1B EUR -464.9
AU
CSL Ltd
ASX:CSL
137B AUD 62.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.4B USD 21.8
US
Seagen Inc
F:SGT
39.3B EUR -56.1
NL
argenx SE
XBRU:ARGX
36.5B EUR -106.4
 
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/FCFF: 29.9
Negative Multiple: -2.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -241 279.4
US
Abbvie Inc
NYSE:ABBV
23.8
US
Amgen Inc
NASDAQ:AMGN
30
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -72.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -464.9
AU
CSL Ltd
ASX:CSL
62.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
21.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.1
NL
argenx SE
XBRU:ARGX
Negative Multiple: -106.4

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A